BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 35855837)

  • 1. Expression of DNA Helicase Genes Was Correlated with Homologous Recombination Deficiency in Breast Cancer.
    Long M; Liu H; Wu J; Wang S; Liao X; Liu Y; Hu T
    Comput Math Methods Med; 2022; 2022():5508301. PubMed ID: 35855837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
    Timms KM; Abkevich V; Hughes E; Neff C; Reid J; Morris B; Kalva S; Potter J; Tran TV; Chen J; Iliev D; Sangale Z; Tikishvili E; Perry M; Zharkikh A; Gutin A; Lanchbury JS
    Breast Cancer Res; 2014 Dec; 16(6):475. PubMed ID: 25475740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
    Telli ML; Timms KM; Reid J; Hennessy B; Mills GB; Jensen KC; Szallasi Z; Barry WT; Winer EP; Tung NM; Isakoff SJ; Ryan PD; Greene-Colozzi A; Gutin A; Sangale Z; Iliev D; Neff C; Abkevich V; Jones JT; Lanchbury JS; Hartman AR; Garber JE; Ford JM; Silver DP; Richardson AL
    Clin Cancer Res; 2016 Aug; 22(15):3764-73. PubMed ID: 26957554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optical Genome Mapping: Integrating Structural Variations for Precise Homologous Recombination Deficiency Score Calculation.
    Sahajpal NS; Mondal AK; Vashisht A; Singh H; Pang AWC; Saul D; Nivin O; Hilton B; DuPont BR; Kota V; Savage NM; Hastie AR; Chaubey A; Kolhe R
    Genes (Basel); 2023 Aug; 14(9):. PubMed ID: 37761823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types.
    Budczies J; Kluck K; Beck S; Ourailidis I; Allgäuer M; Menzel M; Kazdal D; Perkhofer L; Kleger A; Schirmacher P; Seufferlein T; Stenzinger A
    J Pathol Clin Res; 2022 Jul; 8(4):371-382. PubMed ID: 35384413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers.
    Watkins JA; Irshad S; Grigoriadis A; Tutt AN
    Breast Cancer Res; 2014 Jun; 16(3):211. PubMed ID: 25093514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homologous recombination deficiency and ovarian cancer.
    Ledermann JA; Drew Y; Kristeleit RS
    Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of homologous recombination deficiency from Oncomine Comprehensive Assay Plus correlating with SOPHiA DDM HRD Solution.
    Kang J; Na K; Kang H; Cho U; Kwon SY; Hwang S; Lee A
    PLoS One; 2024; 19(3):e0298128. PubMed ID: 38527014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests.
    Meijer TG; Nguyen L; Van Hoeck A; Sieuwerts AM; Verkaik NS; Ladan MM; Ruigrok-Ritstier K; van Deurzen CHM; van de Werken HJG; Lips EH; Linn SC; Memari Y; Davies H; Nik-Zainal S; Kanaar R; Martens JWM; Cuppen E; Jager A; van Gent DC
    Oncogene; 2022 Jun; 41(26):3498-3506. PubMed ID: 35662281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concordance between single-nucleotide polymorphism-based genomic instability assays and a next-generation sequencing-based homologous recombination deficiency test.
    Cristescu R; Liu XQ; Arreaza G; Chen C; Albright A; Qiu P; Marton MJ
    BMC Cancer; 2022 Dec; 22(1):1310. PubMed ID: 36517748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homologous recombination proficiency in ovarian and breast cancer patients.
    Creeden JF; Nanavaty NS; Einloth KR; Gillman CE; Stanbery L; Hamouda DM; Dworkin L; Nemunaitis J
    BMC Cancer; 2021 Oct; 21(1):1154. PubMed ID: 34711195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential value of the homologous recombination deficiency signature we developed in the prognosis and drug sensitivity of gastric cancer.
    Wu X; Wang Q; Liu P; Sun L; Wang Y
    Front Genet; 2022; 13():1026871. PubMed ID: 36468004
    [No Abstract]   [Full Text] [Related]  

  • 13. Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors.
    Paulet L; Trecourt A; Leary A; Peron J; Descotes F; Devouassoux-Shisheboran M; Leroy K; You B; Lopez J
    Eur J Cancer; 2022 May; 166():87-99. PubMed ID: 35279473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?
    Pawlyn C; Loehr A; Ashby C; Tytarenko R; Deshpande S; Sun J; Fedorchak K; Mughal T; Davies FE; Walker BA; Morgan GJ
    Leukemia; 2018 Jul; 32(7):1561-1566. PubMed ID: 29467487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homologous recombination deficiency prediction using low-pass whole genome sequencing in breast cancer.
    Liu Y; Li Y; Zhang MZ; Chen D; Leng Y; Wang J; Han BW; Wang J
    Cancer Genet; 2023 Apr; 272-273():35-40. PubMed ID: 36758499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PARP inhibitors for BRCA wild type ovarian cancer; gene alterations, homologous recombination deficiency and combination therapy.
    Matsumoto K; Nishimura M; Onoe T; Sakai H; Urakawa Y; Onda T; Yaegashi N
    Jpn J Clin Oncol; 2019 Aug; 49(8):703-707. PubMed ID: 31242303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Homologous recombination repair deficiency as a predictive biomarker : Basic mechanisms and detection methods].
    Pfarr N; Merkelbach-Bruse S
    Pathologe; 2021 Jul; 42(4):391-398. PubMed ID: 34152463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?
    Gourley C; Miller RE; Hollis RL; Ledermann JA
    Curr Opin Oncol; 2020 Sep; 32(5):442-450. PubMed ID: 32796232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determining PARP Inhibition as a Treatment Strategy in Melanoma Based on Homologous Recombination Deficiency-Related Loss of Heterozygosity.
    Zhou A; Butt O; Ansstas M; Mauer E; Khaddour K; Ansstas G
    J Natl Compr Canc Netw; 2023 Jul; 21(7):688-693.e3. PubMed ID: 37433433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.